Report LibraryAll Reports
Datamonitor Healthcare I&I Disease Analysis: Wet Age-Related Macular Degeneration (Wet AMD)
May 10, 2021
Due to their ability to improve clinical outcomes and treat a more comprehensive patient population, vascular endothelial growth factor (VEGF) inhibitors have become the standard treatment used in wet age-related macular degeneration (wet AMD).
Currently, the use of photodynamic therapy with Visudyne, both alone and in combination with other treatments, is principally restricted to the second line of therapy and/or patients with the retinal angiomatous proliferation (RAP) or polypoidal choroidal vasculopathy (PCV) subtypes of AMD.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology)|